CelTOS Immunogen Composition for Durable Anti-Parasite Vaccination

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The lack of an effective and commercially available vaccine impedes the prevention and control of malaria, which affects millions annually, necessitating a new approach in malaria vaccine development.

Innovation Solution

Development of novel CelTOS immunogens and antibodies targeting specific epitopes in Plasmodium, Babesia, and Theileria parasites, including variants with altered pore-forming activity and adjuvants, to induce a protective immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional malaria vaccine approaches are used, then vaccine development progresses, but the effectiveness and durability of protection remain insufficient

Engineering Contradiction:

Improvevaccine effectivenessVSAvoidprotection duration

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The vaccine composition is segmented into multiple distinct components: CelTOS protein antigen, adjuvant, and optional stabilizers. This segmentation allows each component to perform its specific function optimally - CelTOS provides targeted epitope recognition, adjuvant enhances immune response durability, and stabilizers maintain protein conformation, collectively resolving the contradiction between effectiveness and protection duration

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention creates a composite vaccine formulation combining CelTOS protein with adjuvants and stabilizers. This composite approach integrates multiple functional elements that work synergistically - the adjuvant extends protection duration while CelTOS ensures effectiveness, directly addressing the technical contradiction

Inventive Principle:

Principle #40Composite materials

2Reliability

If CelTOS immunogens are designed to maintain native pore-forming activity, then parasite traversal function is preserved, but immune response may be suppressed due to functional tolerance

Engineering Contradiction:

Improveimmune response efficacyVSAvoidpore-forming activity

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The invention applies parameter changes by introducing specific point mutations (e.g., E143Q, E143A) in the CelTOS protein sequence. These mutations alter the pore-forming parameter while preserving the overall protein structure and immunogenic epitopes, thereby enhancing immune response efficacy while maintaining sufficient parasite traversal function for vaccine effectiveness

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention extracts the essential immunogenic epitopes from the full-length CelTOS protein while removing or reducing the pore-forming functional domains through targeted mutations. This extraction allows the vaccine to present immunodominant epitopes for robust immune response while minimizing functional tolerance that would suppress immunity

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS12544441B2Compositions comprising CelTOS immunogens and antibodies and method of use thereof

Publication Date: 2026.02.10 UNIV OF SOUTH FLORIDA

AI summary

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.